Evidence map›Paper›PMID 40104187›Full record

ArticleWorld journal of transplantation2025

Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study.

Matthew G Garas, Luis Calzadilla-Bertot, Briohny W Smith, Luc Delriviere, Byron Jaques, Lingjun Mou, Leon A Adams, Gerry C MacQuillan, George Garas, Gary P Jeffrey and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matthew G GarasMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia. matt.garas01@gmail.com.
Luis Calzadilla-BertotMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Briohny W SmithDepartment of Hepatology, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Luc DelriviereDepartment of Surgery, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Byron JaquesDepartment of Surgery, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Lingjun MouDepartment of Surgery, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Leon A AdamsMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Gerry C MacQuillanMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
George GarasMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Gary P JeffreyMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Michael C WallaceMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Liver transplantation (LT) offers the most effective treatment. HCC recurrence is the strongest risk factor that decreases post-LT survival in patients transplanted for HCC. The rate of HCC recurrence is generally reported as 8%-20% in the literature. Many predictors of HCC have already been researched, however, to our knowledge there are no published studies on this topic using Australian data.

aimTo determine the rate and identify predictors of HCC recurrence in a contemporary Western Australian LT cohort.

methodsWe performed a retrospective cohort study of all liver transplants in patients with HCC at Sir Charles Gairdner Hospital between 2006 and 2021. Data was collected from various health record databases and included recipient demographics, serum biochemistry, radiology, operation notes, explant histopathology and details of recurrence. Overall survival of HCC patients post-LT, stratified for recurrence, was calculated by Kaplan Meier analysis. Univariate and multivariate Cox regression was used to determine predictors of HCC recurrence post-LT.

resultsBetween 1/1/2006 and 12/31/2021, 119 patients were transplanted with HCC. 8.4% of subjects developed recurrent HCC after LT with median follow-up time of 5.4 years. The median time to recurrence was 2.9 years ± 0.75 years. When comparing baseline characteristics, a greater proportion of subjects with recurrence had common characteristics on explant histopathology, including > 3 viable nodules (

conclusionHCC recurrence was low at 8.4% in this contemporary Australian cohort, however it significantly impacted post-LT survival. Further studies are required to confirm predictors of recurrence and improve recipient outcomes.

Indexed as

Australian dataHepatocellular carcinomaLiver cancerLiver transplantationPost-transplant survivalPredictorsRecurrence

Identifiers

PMID40104187
PMCPMC11612889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.